LONG-TERM USE OF BISPHOSPHONATES
In a woman being treated to prevent loss of bone mass, the side-effect profile of the medication and the need to measure its effectiveness require regular follow-up visits. Effective October 1, code V58.68 (Long-term [current] use of bisphosphonates) should be reported for these follow-up visits. The code can be also used to support ordering follow-up bone densitometry.
Medications that might be applicable here are alendronate (Fosamax), ibandronate (Boniva), risedronate (Actonel), and zoledronic acid (Reclast).
Download a free copy of the complete addenda of ICD-9-CM code changes that have been made for fiscal year 2012 at: www.cdc.gov/nchs/icd/icd9cm_addenda_guidelines.htm
We want to hear from you! Tell us what you think.